Raf holds a MSc in Biochemistry and Biotechnology from the University of Leuven (KUL) and an MBA from Vlerick Business School (Belgium).
Raf joined Korys in 2017. Prior to this, he spent 8 years in the European biotech sector. His career started at Eurogentec, now a part of the Kaneka corporation. Subsequently, Raf was active at Apitope, helping the company finance their drug development and out-license its compounds.